People: 3SBio Inc (SSRX.O)
16.56USD
21 May 2013
$-0.02 (-0.12%)
$16.59
$16.55
$16.59
$16.54
241,399
165,048
$16.70
$10.15
Su, Dongmei
Brief Biography
Dr. Dongmei Su serves as Vice President - Research & Development, Chief Technology Officer, Director of 3SBio Inc. She is the named co-inventor for four of company's patents. Ms. Su joined Shenyang Sunshine in 1993. She served as director of research and development and manufacturing since 1997. She received her bachelor’s degree in biochemical engineering from Jilin University in 1992, and her master’s and doctor’s degree in microbiology and pharmacology from Shenyang Pharmaceutical University in 2001 and 2010, respectively.
Basic Compensation
| Total Annual Compensation, | Long-Term Incentive Plans, | All Other, | Fiscal Year Total, |
|---|---|---|---|
| -- | -- | -- | -- |
Options Compensation
| Quantity | Market Value | |
|---|---|---|
| Excercisable | -- | -- |
| Unexercisable | -- | -- |
| Excercised | -- | -- |
| Name | Fiscal Year Total |
|---|---|
Jing Lou |
-- |
Bo Tan |
-- |
Bin Huang |
-- |
Ke Li |
-- |
Dongmei Su |
-- |
Peiguo Cong |
-- |
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
